Exelixis Inc. (EXEL)
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
A Dive into Exelixis (EXEL) International Revenue Trends and Forecasts
Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Here's Why Exelixis (EXEL) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL or LQDA: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Liquidia Corporation (LQDA). But which of these two stocks offers value investors a better bang for their buck right now?
Exelixis Reports Solid Earnings—Are New Highs Back on the Table?
Exelixis Inc. NASDAQ: EXEL stock is down about 2% in early trading the day after the company delivered a solid, but mixed earnings report. The company reported earnings per share (EPS) of 94 cents, which was 27% above the consensus estimate and 95% higher on a year-over-year (YoY) basis.
EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus
Exelixis tops Q4 estimates with new buybacks boosting momentum. Cabometyx sales climb and zanzalintinib advances toward FDA review.
Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript
Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript
Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key Metrics
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates
Exelixis (EXEL) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.55 per share a year ago.
2 Intriguing Medical Stocks to Watch as Q4 Results Approach: EXEL, GILD
With their Q4 results approaching after-market hours on Tuesday, February 10, Exelixis (EXEL) and Gilead Sciences (GILD) are two top-performing medical stocks to consider.
